Bavarian Nordic gains US patent for its MVA technology  

The US Patent and Trademark Office has issued a patent for Bavarian Nordic's MVA vaccine technology

Biopharmaceutical company Bavarian Nordic has been granted a patent by the US Patent and Trademark Office for its MVA (Modified Vaccinia Ankara) technology. This forms the basis for a number of prophylactic and therapeutic methods which can prevent or treat different forms of infectious diseases such as smallpox and HIV, as well as cancer. The new patent specifies that the vaccine does not replicate in human cells.

Asger Aamund, chairman of Bavarian Nordic says the patent strengthens the company's market position: "It is difficult to see how our competitors will be able to make MVA and 3rd generation small pox vaccines without getting into conflict with our patent", he comments.

Annette Rye Larsen, pharmaceutical analyst at Gudme Raaschou, says that with the new patent Bavarian Nordic will be one step closer to an order for smallpox vaccine from the US health authorities. The order is expected to be 80 million doses worth USD 900 mn (DKK 5.6 bn). Bavarian Nordic says the US authorities have advised that they will make a decision on the supplier before the end of 2005. The news is reported by financial daily newspaper Børsen.

Link > Bavarian Nordic 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×